Unlock instant, AI-driven research and patent intelligence for your innovation.

Polymorph

A crystal form and drug technology, applied in the field of polymorphs, can solve problems such as difficult handling

Inactive Publication Date: 2015-08-26
ONCOLOGY RES INT
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Where the drug is relatively hygroscopic, it was found to absorb sufficient water to make reproducible dosing and material handling difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polymorph
  • Polymorph
  • Polymorph

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1 Polymorphic form isolated from methanol (comparative example)

[0064] The hydrated form of compound I (1.00 g) was dried by stripping twice from methanol:chloroform 2:1. It was then dissolved in refluxing methanol (50 mL) and cooled slowly (over several hours) before stirring at ambient temperature. The product was collected by filtration and washed with methanol, then dried under vacuum.

Embodiment 2

[0065] Example 2 Polymorphic Forms of Compounds of the Invention

[0066] Compound I (48.0 g, hydrated form) was stirred in 2-propanol (638 mL) for 2 hours, then heated to 75° C. with stirring at 0.5° C. / min for 110 minutes, then stirred at 75° C. for 2 hours. The slurry was then cooled to 20°C at 0.3°C / min for 183 minutes to 20°C and then stirred at 20°C under nitrogen for 16 hours. The resulting slurry was filtered (glass funnel P3) and the filter cake was washed with 2-propanol (200 mL). The product was dried under vacuum at ambient temperature for 3 days to yield the polymorphic form of Compound 1 of the invention.

Embodiment 3

[0067] Example 3 Differential Scanning Calorimetry

[0068] DSC data were acquired on a Mettler Toledo DSC1 system using standard STARe software. Samples were prepared by manually pressing material into standard 25 microliter aluminum pans and running a standard scan protocol with a temperature ramp of 5 degrees / minute under a 50 mL / minute headspace nitrogen purge flow. The instrument is calibrated with reference standard melting points of indium and tin. Onset, peak and glass transition temperatures were determined graphically with Mettler Toledo STARe software. The results of the analysis of the materials produced in Examples 1 and 2 are in figure 1 and 2 shown in .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a new polymorphic form of the compound diosgenyl α-L-rhamnopyranosyl-(1->2)-β-D-glucopyranoside (compound (I)) and pharmaceutical compositions containing this polymorph

Description

technical field [0001] The present invention relates to novel polymorphic forms of the compound diosgenyl α-L-rhamnopyranosyl-(1->2)-β-D-glucopyranoside and to compounds comprising the polymorphic forms The pharmaceutical composition of the substance. Background technique [0002] The compound diosgenin α-L-rhamnopyranosyl-(1->2)-β-D-glucopyranoside (compound I) is a known natural compound. This compound shows significant promise as a pharmaceutically active agent for the treatment of many medical conditions, and based on the profile of activity exhibited by this compound, clinical development of this compound is underway. [0003] [0004] The acceptable level of pharmaceutical activity against the target of interest is only one of the important variables that must be considered in the development of a drug suitable for mass production and eventual commercial use. For example, in the formulation of pharmaceutical compositions, it is essential that the pharmaceut...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07J71/00A61K31/7048
CPCC07J71/00A61K31/7048C07B2200/13C07J71/0005
Inventor 大卫·米拉尔·沃克菲利普·安德鲁·马歇尔
Owner ONCOLOGY RES INT